Pfizer 과거 순이익 실적
과거 기준 점검 0/6
Pfizer의 수입은 연평균 -25.8%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 8.2% 증가했습니다. 매출은 연평균 5%의 비율로 감소해 왔습니다. Pfizer의 자기자본이익률은 8.3%이고 순이익률은 11.8%입니다.
핵심 정보
-25.80%
순이익 성장률
-26.09%
주당순이익(EPS) 성장률
| Pharmaceuticals 산업 성장률 | 5.95% |
| 매출 성장률 | -5.01% |
| 자기자본이익률 | 8.32% |
| 순이익률 | 11.81% |
| 최근 순이익 업데이트 | 29 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 03
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.Seeking Alpha • May 01
Pfizer: Why You Should Double Down Into Q1
Summary Pfizer remains a high-conviction, undervalued Strong Buy with a robust pipeline and aggressive growth in oncology and obesity platforms. PFE's 2026 guidance reaffirmation is the key near-term catalyst, with management targeting $59.5–$62.5B revenue and $2.8–$3 EPS despite patent expirations. Onshoring high-margin production and aggressive cost-cutting are central to de-risking LOE headwinds and expanding operating margins through 2027. At 8.13x P/E and a 6.4% dividend yield, PFE offers compelling value versus peers, with risks around patent cliffs and obesity platform execution. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 19
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.내러티브 업데이트 • Apr 05
PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.내러티브 업데이트 • Mar 22
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.내러티브 업데이트 • Mar 08
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.내러티브 업데이트 • Feb 21
PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.내러티브 업데이트 • Feb 07
PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.내러티브 업데이트 • Jan 24
PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.내러티브 업데이트 • Jan 10
PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.분석 기사 • Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...내러티브 업데이트 • Dec 25
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.분석 기사 • Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...
내러티브 업데이트 • Dec 11
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.내러티브 업데이트 • Nov 13
PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.분석 기사 • Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...Seeking Alpha • Apr 30
Pfizer's Q1 Update May Mark A Bottom In The Stock
Summary Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again. PFE stock is trading at trough valuations and at a larger-than-usual discount vs peers. So I think there is some decent margin of safety. Technical analysis vs SPX500 suggests PFE may be forming a bottom, but strong buyer signals are still absent. Read the full article on Seeking AlphaSeeking Alpha • Apr 23
Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Summary Pfizer Inc.'s stock has performed poorly despite massive COVID-19 earnings, trading at a 12-year low due to flawed M&A deals and high debt levels. The discontinuation of danuglipron, a potential obesity drug, highlights Pfizer's struggle to develop successful new drugs, impacting its market position. Pfizer faces significant challenges including patent expiries, drug pricing controls, and questionable management decisions, casting doubt on its future performance. Despite these issues, Pfizer's high dividend yield and substantial revenue generation provide some investor appeal, but I maintain a "Hold" rating ahead of Q1 earnings. Read the full article on Seeking Alpha매출 및 비용 세부 내역
매출 및 비용 세부 내역
Pfizer가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 29 Mar 26 | 63,315 | 7,479 | 12,894 | 10,710 |
| 31 Dec 25 | 62,579 | 7,746 | 12,964 | 10,437 |
| 28 Sep 25 | 62,785 | 9,797 | 13,973 | 10,131 |
| 29 Jun 25 | 63,833 | 10,728 | 14,005 | 10,205 |
| 30 Mar 25 | 62,464 | 7,867 | 14,333 | 10,521 |
| 31 Dec 24 | 63,627 | 8,020 | 14,771 | 10,822 |
| 29 Sep 24 | 60,433 | 4,274 | 14,155 | 10,494 |
| 30 Jun 24 | 56,223 | -2,593 | 14,139 | 10,611 |
| 31 Mar 24 | 55,946 | -288 | 13,908 | 10,564 |
| 31 Dec 23 | 59,554 | 2,134 | 13,836 | 10,679 |
| 01 Oct 23 | 69,274 | 10,469 | 13,561 | 11,420 |
| 02 Jul 23 | 78,420 | 21,494 | 13,394 | 11,435 |
| 02 Apr 23 | 93,154 | 29,035 | 13,258 | 11,621 |
| 31 Dec 22 | 101,175 | 31,366 | 12,200 | 11,426 |
| 02 Oct 22 | 99,878 | 29,953 | 11,325 | 11,260 |
| 03 Jul 22 | 101,275 | 29,481 | 10,038 | 11,243 |
| 03 Apr 22 | 92,433 | 25,410 | 9,400 | 10,667 |
| 31 Dec 21 | 81,288 | 22,413 | 9,562 | 10,360 |
| 03 Oct 21 | 68,877 | 19,485 | 9,714 | 9,972 |
| 04 Jul 21 | 55,119 | 12,236 | 11,676 | 9,589 |
| 04 Apr 21 | 46,084 | 9,032 | 11,454 | 9,184 |
| 31 Dec 20 | 41,651 | 6,630 | 11,418 | 8,709 |
| 27 Sep 20 | 32,334 | 212 | 11,006 | 8,084 |
| 28 Jun 20 | 34,737 | 6,977 | 10,565 | 7,727 |
| 29 Mar 20 | 38,137 | 9,427 | 11,637 | 7,716 |
| 31 Dec 19 | 40,905 | 10,707 | 12,766 | 7,721 |
| 29 Sep 19 | 53,039 | 16,211 | 13,755 | 7,891 |
| 30 Jun 19 | 53,656 | 12,638 | 14,050 | 7,948 |
| 31 Mar 19 | 53,859 | 11,464 | 14,004 | 7,914 |
| 31 Dec 18 | 40,825 | 3,824 | 12,149 | 7,713 |
| 30 Sep 18 | 53,373 | 23,808 | 14,481 | 7,827 |
| 01 Jul 18 | 53,244 | 22,545 | 14,492 | 7,686 |
| 01 Apr 18 | 52,673 | 21,746 | 14,509 | 7,673 |
| 31 Dec 17 | 52,546 | 21,305 | 14,606 | 7,645 |
| 01 Oct 17 | 52,471 | 9,791 | 14,546 | 7,843 |
| 02 Jul 17 | 52,347 | 8,308 | 14,608 | 7,861 |
| 02 Apr 17 | 52,598 | 7,281 | 14,959 | 7,826 |
| 31 Dec 16 | 52,824 | 7,198 | 14,894 | 7,858 |
| 02 Oct 16 | 53,243 | 6,270 | 14,956 | 7,652 |
| 03 Jul 16 | 52,286 | 7,036 | 14,697 | 7,797 |
| 03 Apr 16 | 50,992 | 7,615 | 14,339 | 7,787 |
| 31 Dec 15 | 48,851 | 6,948 | 14,325 | 7,646 |
| 27 Sep 15 | 47,922 | 8,366 | 13,640 | 7,366 |
| 28 Jun 15 | 48,196 | 8,913 | 13,666 | 7,135 |
양질의 수익: PFE는 $10.7B 규모의 큰 일회성 손실이 있어 29th March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.
이익 마진 증가: PFE의 현재 순 이익률 (11.8%)은 지난해 (12.6%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: PFE의 수익은 지난 5년 동안 연평균 25.8% 감소했습니다.
성장 가속화: PFE은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.
수익 대 산업: PFE은 지난 1년 동안 수익이 감소(-5%)하여 Pharmaceuticals 업계 평균(-7%)과 비교하기 어렵습니다.
자기자본이익률
높은 ROE: PFE의 자본 수익률(8.3%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/07 23:46 |
| 종가 | 2026/05/07 00:00 |
| 수익 | 2026/03/29 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Pfizer Inc.는 44명의 분석가가 다루고 있습니다. 이 중 26명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |